Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Hosted on MSN

Peptide bridge enables cofactor channeling in fusion enzyme and cuts NADPH use

Oxidoreductases are key enzymes in biocatalysis, but their dependence on the cofactor nicotinamide adenine dinucleotide (phosphate) (NAD(P)) presents challenges due to its high consumption and ...
Business Wire

Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics announced today OncoPrism for colorectal, breast, bladder, and kidney cancer. This announcement follows recent Medicare coverage of the OncoPrism ...
Morningstar

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks Cofactor Genomics, a ...